In Brief: Eclipse Surgical Technologies
This article was originally published in The Gray Sheet
Executive Summary
Eclipse Surgical Technologies: Sunnyvale, California-based firm receives investigational device exemption approval from FDA to commence clinical trials of its laser transmyocardial revascularization (TMR) procedure as an adjunct to minimally invasive direct coronary artery bypass surgery (MIDCAB) for the treatment of heart disease. Commercially available in Europe since December, the TMR laser also is undergoing a Phase II study comparing the treatment alone to conventional drug therapy in patients with severe angina. Another Phase II trial underway is comparing TMR and coronary artery bypass graft (CABG) surgery with CABG alone...